Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.
Hiroki HaraTaroh SatohTakashi KojimaTakahiro TsushimaYu SunakawaMorihito OkadaNingning DingHongqian WuLiyun LiTian YuGisoo BarnesKen KatoPublished in: Esophagus : official journal of the Japan Esophageal Society (2024)
ClinicalTrials.gov: NCT03430843.